Changes

no edit summary
Line 2,156: Line 2,156:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
|[[HAEM5:T-lymphoblastic leukaemia / lymphoma, NOS|T-lymphoblastic leukaemia / lymphoma, NOS]]||Disease|| || || || || ||HD|| ||
+
|[[HAEM5:T-lymphoblastic leukaemia / lymphoma, NOS|T-lymphoblastic leukaemia / lymphoma, NOS]]||Disease|| || || || || ||SK|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,170: Line 2,170:  
|
 
|
 
|
 
|
|HD
+
|SK
 
|
 
|
 
|
 
|
Line 2,206: Line 2,206:  
|
 
|
 
|-
 
|-
|[[HAEM5:NK-large granular lymphocytic leukaemia|NK-large granular lymphocytic leukaemia]]||Disease||Michelle Don, MD, MS
+
|[[HAEM5:NK-large granular lymphocytic leukaemia|NK-large granular lymphocytic leukaemia]]||Disease||Hailee St. Louis (trainee);
 +
Michelle Don, MD, MS
 
|3/17/24
 
|3/17/24
 
|6/30/24
 
|6/30/24
Line 2,312: Line 2,313:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
|[[HAEM5:Indolent T-cell lymphoma of the gastrointestinal tract|Indolent T-cell lymphoma of the gastrointestinal tract]]||Disease||PENDING
+
|[[HAEM5:Indolent T-cell lymphoma of the gastrointestinal tract|Indolent T-cell lymphoma of the gastrointestinal tract]]||Disease||
 
| || || || ||SK|| ||
 
| || || || ||SK|| ||
 
|Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract
 
|Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract
Line 2,347: Line 2,348:  
|
 
|
 
|-
 
|-
|[[HAEM5:Intestinal T-cell lymphoma, NOS|Intestinal T-cell lymphoma, NOS]]||Disease||PENDING
+
|[[HAEM5:Intestinal T-cell lymphoma, NOS|Intestinal T-cell lymphoma, NOS]]||Disease||
 
| || || || ||SK|| ||
 
| || || || ||SK|| ||
 
|Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS)
 
|Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS)
Line 2,355: Line 2,356:  
|
 
|
 
|-
 
|-
|[[HAEM5:Hepatosplenic T-cell lymphoma|Hepatosplenic T-cell lymphoma]]||Disease||Michelle Don, MD, MS
+
|[[HAEM5:Hepatosplenic T-cell lymphoma|Hepatosplenic T-cell lymphoma]]||Disease||Forough Sargolzaeiaval (trainee);
 +
Michelle Don, MD, MS
 
|3/19/24
 
|3/19/24
 
|6/30/24
 
|6/30/24
Line 2,391: Line 2,393:  
|
 
|
 
|-
 
|-
|[[HAEM5:Breast implant-associated anaplastic large cell lymphoma|Breast implant-associated anaplastic large cell lymphoma]]||Disease||PENDING
+
|[[HAEM5:Breast implant-associated anaplastic large cell lymphoma|Breast implant-associated anaplastic large cell lymphoma]]||Disease||
 
| || || || ||SK|| ||
 
| || || || ||SK|| ||
 
|Breast Implant-Associated Anaplastic Large Cell Lymphoma
 
|Breast Implant-Associated Anaplastic Large Cell Lymphoma
Line 2,399: Line 2,401:  
|
 
|
 
|-
 
|-
|[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Rachel Burnside, PhD ||7/28/2023
+
|[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Rachel Burnside, PhD||7/28/2023
 
| ||Pending|| ||SK|| ||prior authors not available
 
| ||Pending|| ||SK|| ||prior authors not available
 
|Angioimmunoblastic T-cell Lymphoma
 
|Angioimmunoblastic T-cell Lymphoma
Line 2,415: Line 2,417:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
|[[HAEM5:Nodal TFH cell lymphoma, NOS|Nodal TFH cell lymphoma, NOS]]||Disease||PENDING
+
|[[HAEM5:Nodal TFH cell lymphoma, NOS|Nodal TFH cell lymphoma, NOS]]||Disease||
 
| || || || ||SK|| ||
 
| || || || ||SK|| ||
 
|Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype
 
|Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype
Line 2,468: Line 2,470:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
|[[HAEM5:Systemic EBV-positive T-cell lymphoma of childhood|Systemic EBV-positive T-cell lymphoma of childhood]]||Disease||PENDING
+
|[[HAEM5:Systemic EBV-positive T-cell lymphoma of childhood|Systemic EBV-positive T-cell lymphoma of childhood]]||Disease||
| || || || ||SK|| ||
+
| || || || ||SK|| ||prior authors not available
 
|Systemic EBV-Positive T-cell Lymphoma of Childhood
 
|Systemic EBV-Positive T-cell Lymphoma of Childhood
 
|Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA
 
|Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA